Where to buy retatrutide: what is legal, what the grey market is, and how to read a COA

By Retatrutide Risk editorial team. Published September 21, 2026. Sources at the end of the page.

"Where to buy retatrutide" is one of the most searched retatrutide queries, and it deserves an answer that is honest about the legal situation rather than one written by a seller. This page sets out the status of the compound, how the market that exists actually works, what a certificate of analysis can and cannot tell you, and the signs that a listing is fraudulent. It does not recommend buying retatrutide. Retatrutide is an investigational compound whose safety has been studied only in supervised trials.

Legal status, country by country in one sentence

Retatrutide is not approved for any use in any country. Eli Lilly has stated that it plans to submit a Biologics License Application to the U.S. Food and Drug Administration in the first quarter of 2027, after completing the manufacturing data package. Until an approval exists there is no prescription product, no pharmacy stock, no compounded version with a legal basis, and no brand name.

In the United States this means that any product sold for human use as retatrutide is an unapproved new drug. Sellers avoid that framing by selling "for research use only", a category that exists for laboratory reagents and that carries no requirement to meet pharmaceutical manufacturing standards. The label is a statement about what the seller claims the product is for, not about what the product is.

The three things that get called "retatrutide"

• The clinical trial supply. Manufactured by Lilly under pharmaceutical quality systems, with documented identity, purity, potency, sterility and stability. Administered only within registered trials. Not for sale.
• A future medicine. If approved, retatrutide would be dispensed by pharmacies against a prescription, in a finished dosage form with a label. This does not exist as of September 2026.
• Research-use lyophilized peptide. Synthesized by contract manufacturers, sold in vials nominally containing a stated number of milligrams of powder, with or without a certificate of analysis, through websites that ship to consumers. This is what every "where to buy" search returns, and it is what this page calls the grey market.

Every figure about efficacy and side effects on this site comes from the first category. Nothing published describes what happens with the third.

How the grey market works

Peptide vendors buy bulk synthesized peptide, or finished vials, and resell them with their own labels. The quality of the product depends on the synthesis, the purification, the filling and the storage, and none of these are inspected by a regulator. The vendor may commission testing of a batch from a third-party laboratory and publish the result; that document is the certificate of analysis (COA).

Prices vary widely for nominally identical products, and a low price says nothing about purity in either direction. The market also includes outright fraud: vials containing no active peptide, vials containing a cheaper peptide, and vials containing the claimed peptide at a fraction of the stated amount.

What a certificate of analysis should show

A COA is the only objective information a buyer can obtain about a grey-market vial, and it is only as good as the laboratory that issued it. A useful COA has the following elements.

Two limits apply even to a good COA. It describes one batch on one date, and it does not test the vial you receive. And it says nothing about what the compound does in a person; purity is not safety.

Signs of a fraudulent or misleading listing

• Claims of FDA approval, "pharmaceutical grade" or "clinical grade". None of these can be true for retatrutide.
• Dosing instructions, before-and-after photos, or references to weight loss in the listing. A seller who instructs on human use is contradicting the research-use label it relies on.
• A COA with no laboratory name, no batch number, or a purity figure of exactly 99.9% with no chromatogram.
• Testimonials and star ratings for an injectable research chemical.
• Pressure tactics: countdown timers and "last batch" claims on a product that is synthesized to order.
• Payment only by cryptocurrency or wire transfer with no refund policy, which shifts all risk to the buyer.
• Any reference to "GLP-3" as an approved drug class. See GLP-3 peptide.

What "research use only" means in practice

The phrase places the product outside the regulatory framework for medicines. The seller does not warrant identity, purity, sterility or potency for human use, and a buyer has no consumer protection comparable to that for a licensed medicine. Sellers who operate carefully keep their listings free of human-use claims, publish independent COAs with batch numbers, and state plainly that the product is not for human consumption. One example of such a listing is RP at OXpeptides, research use only; it is linked here as an example of the format, not as a recommendation to buy or use retatrutide. This site does not sell anything, and the bar at the top of the page is its only commercial link.

Why the trial results do not transfer

The results and side effects reported on this site were measured in participants who received a product of known concentration, escalated by protocol, monitored with laboratory tests and electrocardiograms, and excluded for conditions that raised their risk. A grey-market vial removes every one of those conditions. The reconstitution article explains how concentration and dosing errors arise at the bench, and the dosage article explains why forum dosing charts are not trial protocols.

What to expect over the next years

If the FDA accepts and approves an application filed in early 2027, a prescription product could follow in the United States, with a label defining doses, warnings and contraindications. Only then will there be a legal, quality-assured way to obtain retatrutide for human use. The FDA approval article tracks the timeline as it is known.